Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04604704 · ClinicalTrials.gov registry record · Phase 2
Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
A Phase 2 study, sponsored by AgelessRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT04604704 is a Phase 2 study that has completed, run by AgelessRx. The registered enrollment target is 36 participants.
The verdict
NCT04604704, a Phase 2 study, has completed, sponsored by AgelessRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.
Interventions
- DRUG Naltrexone
- DIETARY_SUPPLEMENT NAD+
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-01-28 |
| Est. Completion | 2023-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04604704
The ClinicalTrials.gov registry entry for NCT04604704 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AgelessRx, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Naltrexone is the first listed.
NCT04604704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04604704 about?
NCT04604704 is a clinical study titled "Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome". Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.
What is the current status of trial NCT04604704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2021-01-28. Estimated completion is 2023-01-23.
What interventions are being tested in trial NCT04604704?
The interventions under investigation include: Naltrexone (DRUG), NAD+ (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04604704?
This trial is sponsored by AgelessRx, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.